VIPoma surgery

	VIPoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating VIPoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
VIPoma surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of VIPoma surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on VIPoma surgery
CDC on VIPoma surgery
VIPoma surgery in the news
Blogs on VIPoma surgery
Directions to Hospitals Treating VIPoma
Risk calculators and risk factors for VIPoma surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]

Overview

Surgery is the mainstay of treatment for VIPoma. Surgery should be considered after initial symptomatic management of VIPoma inoperable cases. Complete surgical resection of the tumor is the only curative treatment for VIPoma. If the tumor cannot be removed completely, surgical debulking may have palliative effect for control of hormonal symptoms.

Surgery should be considered after initial symptomatic management of VIPoma inoperable cases.
Complete surgical resection of the tumor is the only curative treatment for VIPoma.
The feasibility of surgery depends on the stage of VIPoma at diagnosis.
If the tumor cannot be removed completely, surgical debulking may have palliative effect for control of hormonal symptoms.
In nonresectable liver metastases, hepatic TACE (transarterial chemoembolization) is emerging as a new non-emergency therapeutic modality highly successful for control of VIP-related symptoms.

↑ Vinik A. Vasoactive Intestinal Peptide Tumor (VIPoma) [Updated 2013 Nov 28]. In: De Groot LJ, Beck-Peccoz P, Chrousos G, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: http://www.ncbi.nlm.nih.gov/books/NBK278960/
↑ Blaise A, Girardet JL (1969). "[Study of the magnetic properties of siderophilin]". C R Acad Sci Hebd Seances Acad Sci D. 269 (10): 966–8. PMID 4981295.
↑ Dréanic, Johann; Lepère, Céline; El Hajjam, Mostafa; Gouya, Hervé; Rougier, Philippe; Coriat, Romain (2016). "Emergency therapy for liver metastases from advanced VIPoma: surgery or transarterial chemoembolization?". Therapeutic Advances in Medical Oncology. 8 (5): 383–387. doi:10.1177/1758834016656495. ISSN 1758-8340.